Search results
Roche launches B-cell lymphoma diagnostic assay in Europe
Medical Device Network via Yahoo Finance· 5 days agoRoche’s Ventana B-cell lymphoma diagnostic assay can detect and differentiate B-cell lymphomas and...
Trials to watch: Phase III BCG naïve non-muscle invasive bladder cancer
Clinical Trials Arena via Yahoo Finance· 5 days agoCheckpoint inhibitors in combination with BCG Many big pharma companies are investigating the use of...
The secrets of success with Paul Hudson, CEO of Sanofi, the leader who’s channeling AI to find the...
Fortune via Yahoo Finance· 5 days agoSix months later, COVID appeared in China, and a little later, all over the world. In those early...
Novel GLP-1/Glucagon Drug Promising for Weight Loss
MedPage Today· 1 day agoNovel dual GLP-1 and glucagon agonist pemvidutide reduced weight and lipids with somewhat less muscle loss than expected, the phase II MOMENTUM trial...
‘I’ve saved £44,000 – can I retire as a millionaire at 60?’
The Telegraph· 5 days agoCollective investments simplify things by providing built-in diversification and can save you the...
Truqap Combo Earns EU Approval for Advanced Breast Cancer
Medscape· 4 days agoThe approval is based on positive results from the phase 3 CAPItello-291 trial.
US FDA approves Roche's drug for a chronic blood disorder (June 21)
Reuters via Yahoo News· 4 days agoThe U.S. Food and Drug Administration on Thursday approved Roche's drug for a chronic blood...
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
InvestorPlace· 1 day agoHeart disease drugmaker Alnylam (NASDAQ:ALNY) stock rose sharply on the success of a Phase 3 study...
$35 inhaler price cap expected to save lives in Pa.
WFMZ Eastern Pennsylvania and Western New Jersey· 7 days agoBreathing in the hot air can be a problem for people with asthma, but something that should have asthma patients breathing a little easier: major inhaler...
5 Fidelity Mutual Funds to Buy for Long-Term Gains
Zacks via Yahoo Finance· 4 days agoInvest in Fidelity mutual funds like FIKGX, FIKAX, FSPCX, FSUTX and FPHAX, which have given impressive returns this year and are expected to perform well...